Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI

First Posted Date
2015-07-08
Last Posted Date
2017-09-08
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Target Recruit Count
50
Registration Number
NCT02492230
Locations
🇷🇺

State Research Institute of CIrculation Pathology Novosibirsk, Russian Federation, Novosibirsk, Russian Federation

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-06-03
Last Posted Date
2017-01-24
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
16
Registration Number
NCT02461914

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2015-05-21
Last Posted Date
2016-01-18
Lead Sponsor
Mayo Clinic
Registration Number
NCT02450682
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers

First Posted Date
2015-04-24
Last Posted Date
2015-04-24
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
12
Registration Number
NCT02426060
Locations
🇨🇳

Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan, Hubei, China

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

First Posted Date
2015-04-21
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
33
Registration Number
NCT02422589
Locations
🇺🇸

Cancer Therapy & Research Center UT Health Science Center SC-4, San Antonio, Texas, United States

🇺🇸

Henry Ford Hospital SC, Detroit, Michigan, United States

🇺🇸

Karmanos Cancer Institute Oncology Department, Detroit, Michigan, United States

and more 1 locations

Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-03-18
Last Posted Date
2019-12-11
Lead Sponsor
William S. Middleton Memorial Veterans Hospital
Target Recruit Count
51
Registration Number
NCT02392104

The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT

First Posted Date
2015-03-03
Last Posted Date
2018-05-04
Lead Sponsor
University of Alberta
Target Recruit Count
217
Registration Number
NCT02376803
Locations
🇨🇦

Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-03-03
Last Posted Date
2024-10-14
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
110
Registration Number
NCT02376010
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Torrance, California, United States

© Copyright 2024. All Rights Reserved by MedPath